Not medical advice. Talk to your provider before using any peptide.
Full disclaimerPeptide Schedule Research TeamReviewed Apr 202613 Citations
Tirzepatide targets both GIP and GLP-1 receptors, producing 20-22% body weight loss in important trials. FDA-approved as Zepbound (obesity) and Mounjaro (T2D). GI side effects during titration are the main limiting factor; a black box warning for thyroid tumors applies.
2,500mcg · Weekly
Summary: Add 2mL BAC water to your 5mg vial. Draw to 100.0 units on a U-100 syringe for a 2,500mcg dose. This vial will last 2 doses.
View side effects and safety warnings →
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 2,500mcg | Weekly |
| Moderate | 5mg | Weekly |
| Aggressive | 10mg | Weekly |
Tirzepatide comes in pre-filled pens (brand Zepbound/Mounjaro) and compounded vials (very limited availability since March 2025). For compounded vials: Reconstitution math for a 10 mg vial with 2 mL bacteriostatic water gives you 5 mg/mL. A 2.5 mg dose is 0.5 mL (50 units on an insulin syringe). A 5 mg dose is 1.0 mL (100 units, a full syringe). For a 15 mg vial with 2 mL BAC water, concentration is 7.5 mg/mL. A 7.5 mg dose is 1.0 mL (100 units). A 10 mg dose runs about 1.33 mL, which exceeds a standard 1 mL syringe; either use a 3 mL syringe or reconstitute with 3 mL instead (giving 5 mg/mL, then 2.0 mL per 10 mg dose). The thing most beginners miss: 2.5 mg is not a therapeutic dose for weight loss. It's a tolerability test. Don't judge whether tirzepatide "works" until you've been at 5 mg for at least 4 weeks. Evening injections help most people sleep through the nausea window (4 to 8 hours post-dose).
Dosing based on Zepbound FDA Prescribing Information (2023) — 21 published references.View all sources →
Cross-check your Tirzepatide reconstitution math with AI

Entrepreneur & Longevity Pioneer
Raised RHR +3bpm, lowered HRV -7pts, sleep quality -10%. Halted after 3 weeks.
Pricing updated 2026-04-09
Prices are estimates and vary by source, location, and prescription status.Full pricing breakdown →
Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Tirzepatide targets both GIP and GLP-1 receptors, producing 20-22% body weight loss in important trials. FDA-approved as Zepbound (obesity) and Mounjaro (T2D). GI side effects during titration are the main limiting factor; a black box warning for thyroid tumors applies.